Related Experiment Video
Updated: Feb 24, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.4K
Consensus on Bridges for Barriers to Insulin Therapy
Sanjay Kalra1, Samit Ghosal2, Parag Shah3
1Consultant Endocrinologist, Department of Endocrinology, Bharti Hospital and BRIDE, Karnal, Haryana.
The Journal of the Association of Physicians of India
|August 24, 2017
Summary
Insulin therapy is crucial for glycaemic control but faces barriers. This consensus statement categorizes these barriers and offers solutions to improve insulin use in diabetes management.
Area of Science:
- Endocrinology and Metabolism
- Diabetes Care Management
Background:
- Insulin is a vital, safe, and effective medication for managing blood glucose levels.
- Significant obstacles hinder the widespread adoption and effective utilization of insulin therapy.
Framework:
- Barriers to insulin use are systematically classified into patient/community, physician/provider, and drug/device categories.
- Sub-categorization includes perceived inadequacy, high cost, and lack of benefit or tolerability.
Implementation:
- Patient barriers are addressed through education, support, and counseling.
- Physician barriers are mitigated via enhanced training in diabetes care.
- Drug and device barriers are overcome by optimizing the selection of insulin regimens and delivery systems.
Implications:
- This structured approach facilitates the development of targeted interventions to overcome insulin-use barriers.
- The consensus provides a valuable tool for healthcare professionals to promote proactive diabetes management and improve patient outcomes globally.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
903
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
903
01:15Diabetes: Management and Pharmacotherapy
1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
721
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
721
01:22Diabetes Mellitus: Overview and Type I Subtype
5.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.6K
01:27Insulin Formulations: Types and Delivery
852
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
852
01:25Insulin: Biosynthesis, Chemistry, and Preparation
1.6K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.6K